XANGAI, 2 de julho de 2023 /PRNewswire/ — A Bioheart (02185.HK), juntamente com sua subsidiária holding Angiocare, anuncia o resultado clínico do Iberis-HTN na China Interventional Therapeutics 2023. O Iberis-HTN é um estudo clínico prospectivo, multicêntrico, cego e randomizado para…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.